|Bid||8,269.00 x 0|
|Ask||8,271.00 x 0|
|Day's range||8,142.00 - 8,399.00|
|52-week range||6,499.80 - 8,923.00|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||37.76|
|Earnings date||29 July 2021|
|Forward dividend & yield||2.07 (2.50%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||78.83|
Julie Hyman breaks down Thursday’s business headlines, including: gun manufacturer Remington offering a $33 million settlement to nine families in connection with the 2012 Sandy Hook shooting, Emergent resuming J&J vaccine production in Baltimore, AstraZeneca losing money on its Covid-19 vaccine after vowing to distribute the shot at no profit, and the Ever Given reaching Rotterdam after Suez Canal debacle.
AstraZeneca is considering options for its vaccines business following a series of setbacks with its Covid jab. It could turn the Covid vaccines unit into a profit-making division, partner with another vaccines player, or spin it out, according to sources. It is the first time the FTSE 100 pharma giant has publicly confirmed it is reviewing the future of the business. Ruud Dobber, head of Astra's biopharmaceuticals unit, told Reuters: “We are exploring different options. Before year-end, we will
Here's what you need to know as it played out on Thursday.